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serum lipids and blood pressure. Associations between the course of AIx and potential predictors were
investigated through a mixed effect model. Results: Seventy-six patients (mean (SD) age 62.4 (7.1),
male 67%) were included. The AIx showed a significant annual increase of 0.91% (95% CI 0.21/1.60)
adjusted for baseline. The change in diffusion capacity (DLco), low-density lipoprotein (LDL), and high-
sensitivity c-reactive protein (hsCRP) was independently associated with the increasing evolution of AIx
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Background: Cardiovascular events are, after cancer, the most common cause of death in
COPD patients. Arterial stiffness is an independent predictor of all-cause mortality and
cardiovascular events. Several cross-sectional studies have confirmed increased arterial
stiffness in patients with COPD. Various mechanisms in the development of arterial stiffness
in COPD such as reduced lung function or systemic inflammation have been proposed.
However, clinical predictors of arterial stiffness that had been reported in cross-sectional
studies have not yet been confirmed in a longitudinal setting. We have assessed the course of
augmentation index (AIx) - a measure of systemic arterial stiffness - and possible predictors
in a cohort of COPD patients over a period of up to 7 years.
Methods: COPD patients underwent annual AIx measurement by applanation tonometry for
a maximum duration of 7 years. Additionally, we performed annual assessments of lung function,
blood gases, systemic inflammation, serum lipids and blood pressure. Associations between the
course of AIx and potential predictors were investigated through a mixed effect model.
Results: Seventy-six patients (mean (SD) age 62.4 (7.1), male 67%) were included. The AIx
showed a significant annual increase of 0.91% (95% CI 0.21/1.60) adjusted for baseline. The
change in diffusion capacity (DLco), low-density lipoprotein (LDL), and high-sensitivity
c-reactive protein (hsCRP) was independently associated with the increasing evolution of
AIx (Coef. - 0.10, p<0.001, Coef. 1.37, p=0.003, and Coef. 0.07, p=0.033, respectively).
Conclusion: This study demonstrated a meaningful increase in arterial stiffness in COPD
over time. A greater annual increase in arterial stiffness was associated with the severity of
emphysema (measured by DLco), systemic inflammation, and dyslipidaemia.
Clinical Trial Registration: www.ClinicalTrials.gov, NCT01527773.
Keywords: COPD, cardiovascular risk, arterial stiffness, emphysema, longitudinal,
inflammation, dyslipidaemia
Introduction
Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk
for cardiovascular morbidity and mortality. Cardiovascular disease is considered to be
responsible for up to 30% of the deaths in patients with COPD and represents
the second highest cause of death after cancer.1,2 Chen et al3 meta-analysed an
extensive collection of evidence (29 databases) from large international studies and
confirmed that the risk for cardiovascular disease (peripheral artery disease, ischemic
heart disease, heart failure, cardiac dysrhythmia, diseases of pulmonary circulation) is
increased by up to five times in patients with COPD. The authors pointed out the
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crucial need for the development of strategies to screen for
and reduce cardiovascular risk in COPD patients. Global
cardiovascular risk scores have been established to improve
risk stratification and to predict cardiovascular mortality in
COPD patients.4 Since these risk scores may underestimate
the cardiovascular risk, particularly in early prevention, non-
invasive assessment techniques such as measurement of
arterial stiffness, endothelial function, and carotid intima-
media thickness have been investigated to improve early
detection of vascular dysfunction before it becomes clini-
cally overt.5 Arterial stiffness assessed by pulse wave velo-
city (PWV) and augmentation index (AIx) is a strong
predictor of cardiovascular events and all-cause mortality
in the general population.6 Several cross-sectional studies
have shown increased arterial stiffness in COPD patients
when compared to healthy controls.7,8 Recently,
a longitudinal study of cardiovascular risk in COPD patients
(ARCADE-Study) confirmed increasing PWV in COPD
patients over a period of 2 years.9 Various mechanisms in
the development of arterial stiffness in COPD have been
proposed. They include some classical risk factors for ather-
osclerosis such as smoking, physical inactivity, and aging. In
addition, more COPD specific conditions like airway
obstruction, emphysema, oxidative stress, exacerbations,
systemic inflammation, and increased sympathetic tonus
have been incriminated in the process of increased arterial
stiffness.10 Even though findings on the influence of airflow
limitation and systemic inflammation on arterial stiffness
have been incongruent,8,11,12 a recent review on arterial
stiffness in COPD postulated that these processes may con-
tribute to vascular remodelling and atherosclerosis progres-
sion, possibly leading to cardiovascular events.5 However,
most of the studies assessing arterial stiffness in COPD are
limited by their cross-sectional study-designs. Longitudinal
data on the evolution of arterial stiffness and its possible
predictors in COPD patients are scant. In this study, our
objective was to investigate the longitudinal course of arter-
ial stiffness measured by AIx in a well-characterized cohort
of COPD patients and to evaluate possible predictors that
have been described in cross-sectional studies.
Methods
Subjects
The Obstructive Pulmonary Disease Outcomes Cohort
Study (TOPDOCS) was performed as a prospective, non-
interventional cohort project including mild to very
severe COPD patients from seven pulmonary outpatient
clinics in Switzerland. Initially, this study was conducted
as a cross-sectional study and was later transformed into
a longitudinal study design. The patients were recruited
during outpatient visits or during hospitalization for initi-
ally three annual study visits. Only patients in Zurich,
Switzerland, underwent pulse-wave analysis. Patients
aged between 40 and 75 years with confirmed COPD
according to GOLD-guidelines13 were assessed for elig-
ibility between October 2010 and April 2016. Patients
undergoing exacerbation were included into the study
with a delay of at least 6 weeks. Exclusion criteria
were defined as such: suffering from physical or intel-
lectual impairment prohibiting informed consent or com-
pliance with the protocol.
The study was conducted in accordance with the
declaration of Helsinki and all subjects gave written
informed consent to participate. The Ethics Committee of
the Canton of Zurich approved the study (EK-ZH-NR:
2011–0106) and the study is registered at www.
ClinicalTrials.gov, NCT01527773.
Measurements
All measurements were conducted within 2 hrs on the day
of the annual study visits. Patients were asked to follow
their usual daily routine including their regular alcohol-,
coffee- and medication intake.
Vital Signs
Blood pressure (BP) and heart rate were measured in tripli-
cate separated by one-minute intervals. Measurements were
conducted after resting in supine position for 5 mins in
a quiet room of our hospital with a validated, semi-
automated oscillometric device (Omron, Omron Healthcare
Co, Ltd. Kyoto, Japan). The average of these three blood
pressure measurements was used for further analysis.
Lung Function
All patients underwent standard pulmonary functional test-
ing according to ATS/ERS guidelines.14,15 Forced vital
capacity (FVC), forced expiratory volume in 1 s (FEV1),
residual volume to total lung capacity (RV/TLC), and
diffusing capacity of the lung for carbon monoxide
(DLco) were measured. Only values measured after
bronchodilation are reported.
Exacerbations
Acute exacerbations (AE) were defined as an increase in
patient’s dyspnea, cough, and/or sputum that led to prescrip-
tion of antibiotics and/or corticosteroids. Patients were
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annually asked about their number of AE and the number of
AEs leading to hospitalization during the preceding year.
Patient reports were compared to documents from the gen-
eral practitioner, pulmonologist and hospital to receive most
accurate information on AE. “Frequent exacerbators” were
defined as patients with ≥2 AE per year.
Daily Physical Activity (PA) and Exercise Capacity
Daily physical activity (PA) was measured by
a multisensory activity monitor (SenseWear Pro™;
Bodymedia Inc., Pittsburgh, PA, USA), valid to assess
PA in COPD patients.16 Physical activity level (PAL) as
an objective measure of PA is defined as the total energy
expenditure divided by the resting metabolic rate.17 The
monitor was worn on the upper left arm over the triceps
muscle for 7 consecutive days once a year. Data were
considered valid if the armband was worn at least for 4
days with a minimum of 22.5 hrs/day. Seasonality was
considered in the analysis. Exercise capacity was mea-
sured by 6-mins walk distance (6MWD).18
Comorbidities and Survival
Comorbidities were evaluated every year through review
of the medical history, interviews and physical examina-
tion. The International Classification of Diseases - Tenth
Revision (ICD-10)19 was used for classifying comorbid-
ities. Completely resolved conditions were excluded from
the report. For this sub-study, only diseases associated
with increased cardiovascular risk were analyzed. Follow-
up time reached either from the date of baseline visit to
time of death, or from baseline visit to the final study end
in summer 2016. Furthermore, to assess survival time we
either called the patients, their next relatives, or the gen-
eral practitioner to receive current information on survival
and comorbidities in spring 2019.
Blood Analysis and Blood Gas Analysis
Measurement of high-sensitivity C-reactive protein
(hsCRP), cholesterol, low-density lipoprotein (LDL), high-
density lipoprotein (HDL), and triglyceride (TG) was per-
formed from fresh blood samples.
Arterial blood gas analysis was used to measure the
partial pressure of oxygen (PaO2) and carbon dioxide
(PaCO2). Analysis was performed with ABL 700 series
blood gas analyzer (Radiometer Copenhagen).
Pulse Wave Analysis
Subjects had to rest 10 mins in supine position before pulse
wave analysis. Subsequently, radial artery pulse waveforms
were recorded using the SphygmoCor System (AtCor
Medical, Sydney, NSW, Australia). Approximately 10 radial
pulse waves were measured to generate a corresponding
central aortic pressure waveform using a validated mathe-
matical transfer function.20 As shown in Figure 1, the inflec-
tion point of the aortic pressure waveform corresponds to the
onset of the reflected wave returning from peripheral arteries
and divides the aortic pressure wave into an early and late
systolic peak. This inflection point can be determined with
an algorithm. The augmentation index (AIx) quantifies the
augmentation of central aortic pressure, hence representing
a measure of peripheral arterial wave reflection. AIx can be
calculated as the difference between the second (P2) and the
first systolic peak pressure (P1) and is expressed as the
percentage of central pulse pressure (PP): AIx (%) = [(P2
−P1)/PP] ×100. Since AIx is influenced by heart rate,21,22
the index is adjusted to a heart rate of 75 bpm. SphygmoCor
Px software adjusts the AIx at an inverse rate of 4.8% for
each 10bpm increment. To ensure a high measurement qual-
ity, only measurements with an operator index of 70 and
above were accepted.
Data Analysis and Statistics
All results are shown as mean values (standard deviation
(SD)) or median (25%/75% quartiles) unless otherwise
stated. Statistical analysis was performed with STATA
15.1 (StataCorp, Texas, USA).
Figure 1 Schematic presentation of the pulse wave curve measured at the
A. radialis. After the foot of the pulse (T0), indicating the onset of ejection, the
pressure wave rises to an initial peak where it forms a shoulder (P1). This is the
peak of the primary left ventricular ejection pressure. The second shoulder (P2)
represents the peak of the arterial reflection wave. The difference between P2 and
P1 is called augmentation pressure (AP). The end of ejection (ED) is the point of the
closure of the aortic valve and time of the end of systole. The augmentation index
(AIx) is calculated as the difference between the second (P2) and first (P1) systolic
peak pressure and is expressed as a percentage of the central PP: AIx (%) = [(P2
−P1)/PP] ×100.
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To analyse the cross-sectional association between AIx
at baseline and baseline characteristics, univariate linear
regression models were used. To investigate the change of
AIx over time and the associations between the change in
AIx (dependent variable) and the yearly assessed possible
predictors such as BP, lung function, PA, and comorbid-
ities and their annual changes, univariate mixed effect
models were used. Furthermore, the independent associa-
tion between AIx and possible predictors was analysed
using a multivariate mixed effect regression model invol-
ving variables that showed a univariate regression p-value
of <0.05. Residual analysis of the model was performed to
check the regression assumptions. A two-sided p-value of
<0.05 was considered statistically significant.
Results
Study Participants
Of the 219 patients screened for eligibility in the University
Hospital Zurich between 2010 and 2016, 158 patients attended
the baseline visit. Data from 76 COPD patients with at least
two visits and available AIx measurement were entered for
this sub-study (Figure 2). The mean (SD) age at baseline was
62.4 (7.1) years, 67% were male, and 21% of the COPD
patients were current smokers. The detailed patient character-
istics are shown in Table 1. Mean (min/max) follow-up time
was 2.1 (0.53/6.84) years with annual measurements. During
the follow-up period, 48 patients were analysed at the second
follow-up, 27 at the third follow-up and 15 at the fourth
follow-up. Through the observation period, 18 of the patients
died, 20 patients dropped out due to worsening health status
prohibiting physical presence, and 10 patients underwent lung
transplantation. Around one-fifth of patients refused/withdrew
their will to participate for the first or second follow-up visit.
The baseline AIx did not differ between patients who under-
went follow-up and patients who did not (p=0.395).
Arterial Stiffness and Possible Predictors
at Baseline
At baseline, mean (SD) AIx was 27.1 (8.9) %. Male patients
showed a significantly lower AIx than female patients (Coef.
−5.23, p=0.015). A higher BP was associated with an elevated
AIx (systolic BP: Coef. 0.14, p=0.019; diastolic BP: Coef.
0.27, p=0.09). COPD severity expressed by FEV1%pred. and
PaO2 was significantly associated with a higher AIx (Coef.
−0.11, p=0.019 and −1.35, p=0.029, respectively). Although
missing statistical significance, patients who showed a longer
survival time tend to have a lower AIx compared to patients
who died earlier (Coef. −0.09, p=0.081). Further analysed,
possible predictors are shown in Table 2.
Change in Arterial Stiffness Over Time
AIx showed a significant mean (95% CI) annual increase of
0.83 (0.28/1.38) %, p=0.003), even when adjusted for base-
line AIx (Coef. (95% CI) 0.91 (0.21/1.60) %, p=0.011)
(Table 3). The annual increase of AIx was independent of
the aging of the cohort over time (Coef (95% CI) 0.74 (0.14/
1.34), p=0.015).
Potential Predictors of Arterial Stiffness
Increase Over Time
In the univariate mixed effect model, the amount of annual
increase of AIx was positively associated with the change of
RV/TLC (Coef. 0.05, p=0.034) and the change of DLco
(Coef −0.06, p=0.036) (Figure 3). On the other hand, changes
in FEV1% pred. and blood gases had no effect on the course
of AIx. High LDL (Coef. 0.61, p=0.038) and the intake of
statins (Coef. 1.49, p=0.039) were positively associated with
an increasing AIx over time. In addition, high hsCRP levels,
but not the annual change in hsCRP, were positively asso-
ciated with the AIx course (Coef. 0.07, p=0.017) (Figure 4).
A history of coronary artery disease revealed a significant
positive association with the annual increase of AIx (Coef.
2.04, p=0.041). In contrast, the course of exacerbations,
smoking status, inhalation therapy, and blood pressure did
not show any association with the annual increment of AIx.
All results are presented in Tables 4 and 5. The multivariate
effect model confirmed an independent, positive association
of LDL (Coef. 1.37, p=0.003) and hsCRP (Coef. 0.07,
p=0.033) with an increased evolution of AIx (Table 6). In
addition, the AIx course was independently and negatively
associated with the annual change in DLco (Coef −0.10,
p<0.001). A shorter survival time was not associated with
a greater increase in AIx over time. Due to the high correla-
tion between LDL and statin intake, as well as between DLco
and RV/TLC, statin intake and RV/TCL were removed from
the final multivariate model.
Discussion
This study investigated the longitudinal course of arterial
stiffness and its possible predictors in a well-characterized
cohort of patients with mild to very severe COPD. We
found an annual increase of AIx indicating progressive
rigidity of the arterial wall in COPD patients over time.
Decreasing DLco, a surrogate marker of emphysema, as
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well as increasing systemic inflammation and dyslipidae-
mia enhanced the increasing evolution of arterial stiffness
over time. Our results add novel information to the field of
cardiovascular risk in patients with COPD. By assessing
potential predictors on the course of arterial stiffness, these
data provide additional information useful for predicting
the cardiovascular disease course of COPD patients in
clinical practice.
The mean (SD) AIx (27.1 ± 8.9%) in our cohort was
comparable to former studies assessing arterial stiffness in
163 COPD patients eligible and agreed 
to take part
• Refused participation (47)
• Mental or physical disability (3)
• Language difficulties 
precluding informed consent (6)
• No show up (5)
158 COPD patients attended
219 COPD patients screened 
for eligibility
• No valid AIx measurement (5)
First Follow-Up 
76 COPD patient data
analyzed
• Refused 1. FU measurement (41)
• LTPL before 1. FU (6)
• Death before 1. FU (13)
• Worsening health status (17)
Figure 2 Study flow chart.
Abbreviations: AIx, augmentation index; FU, follow-up; LTPL, lung transplantation.
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COPD patients with similar age, gender ratio and BMI.23
To our knowledge, there are no longitudinal data available
describing the course of arterial stiffness measured by AIx,
neither in COPD patients nor in healthy individuals.
Nevertheless, compared to the suspected annual AIx
course in the general population obtained from cross-
sectional, unselected population-based studies, our study
revealed an elevated annual AIx increase in COPD
patients (0.26–0.38%/year vs 0.91%/year).24 Furthermore,
the increase in AIx was independent of aging in our cohort
over time. The recently published ARCADE study
assessed arterial stiffness measured by PWV in COPD
patients and comparators (current or past smokers, FEV/
FVC>70%) over 2 years. They found similar increase in
the rates of PWV in both groups. However, this study was
limited by differences in smoking status, overt cardiovas-
cular disease, and dropout rates between the two groups.
In addition, arterial stiffness measured by AIx and PWV
are not directly comparable or interchangeable.
Possible mechanisms leading to increased arterial stiffness
like aging, elevated BP, dyslipidaemia, and chronic inflamma-
tion have been extensively reviewed in general cardiovascular
literature.25–27 In COPD, arterial stiffness has been indepen-
dently associated with impairment of lung function, hypoxia,
systemic inflammation, and increased sympathetic tone; fac-
tors that could contribute to the increased cardiovascular risk
in COPD patients.8,11 Further, the severity of emphysema
measured by computed tomography scans has been described
Table 1 Patient Characteristics
N=76
Age, years 62.4 (7.1)
Male/Female 51/25
BMI, kg/m2 25.1 (22.5/27.7)
Current smoker, N (%) 16 (21)
Pack years of smoking, N 40.0 (29.0/58.5)
Systolic blood pressure, mmHg 131.4 (16.9)
Diastolic blood pressure, mmHg 82.1 (9.9)
FVC, % pred. 81.1 (18.3)
FEV1, % pred. 36.0 (27.5/65.0)
RV/TLC, % 54.2 (12.2)
DLco, % pred. 44.0 (35.0/61.0)
PaO2, kPa 9.2 (1.7)
PaCO2, kPa 5.0 (4.5/5.4)
HCO3-, mmol/l 24.9 (24.0/26.2)
hsCRP, mg/l 2.0 (1.0/4.5)
HbA1c, % 5.8 (5.5/6.2)
Antihypertensivum, N (%) 38 (50)
Statins, N (%) 22 (29)
LABA+LAMA+ICS, N (%) 171 (54.63)
Arterial hypertension, N (%) 33 (43)
CAD, N (%) 9 (12)
Diabetes, N (%) 12 (16)
Frequent exacerbators, N (%) 25 (33)
PAL 1.4 (1.3/1.5)
Survival time, months 78 (63/94)
Aortic Augmentation Index, % 27.1 (8.9)
Aortic Augmentation Index, % (women) 30.6 (10.4)
Aortic Augmentation Index, % (men) 25.3 (7.5)
Note: Values are represented as mean (SD) or median (quartiles) unless otherwise
stated.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC,
forced volume capacity; RV, residual volume; TLC, total lung capacity; DLco, diffusion
capacity; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial pressure of
carbon dioxide in arterial blood; LABA, Long-acting beta-agonist; LAMA, Long-acting
muscarinic antagonist; ICS, inhaled corticosteroids; CAD, coronary artery disease;
LDL, low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity
c-reactive protein; PAL, physical activity level.
Table 2 Univariate Regression Analysis of Possible Baseline
Characteristics as Predictors for Baseline Aortic Augmentation
Index
N=76 Coef. 95% CI p-value
Age 0.09 −0.19/0.38 0.517
Male −5.23 −9.39/-1.06 0.015*
Height, cm −0.40 −0.63/-0.17 0.001*
Weight, kg −0.22 −0.30/-0.13 <0.001*
BMI, kg/m2 −0.59 −0.87/-0.30 <0.001*
Current smoker −1.49 −6.48/3.50 0.553
Systolic blood pressure, mmHg 0.14 0.02/0.26 0.019*
Diastolic blood pressure, mmHg 0.27 0.07/0.47 0.009*
FEV1, % pred. −0.11 −0.20/-0.02 0.019*
PaO2, kPa −1.35 −2.55/-0.14 0.029*
PaCO2, kPa 1.71 −1.33/4.76 0.265
Number of exacerbations, N −0.20 −1.42/1.02 0.743
Arterial hypertension −2.07 −6.16/2.01 0.315
CRP, mg/l −0.01 −0.21/0.18 0.903
Survival time, months −0.09 −0.19/0.01 0.081
PAL −9.38 −19.46/0.70 0.068
6MWD, m −0.01 −0.02/0.01 0.357
Note: *p<0.05.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s; RV,
residual volume; TLC, total lung capacity; DLco, diffusion capacity; PaO2, partial
pressure of oxygen in arterial blood; PaCO2, partial pressure of carbon dioxide in
arterial blood; CAD, coronary artery disease; PaO2, partial pressure of oxygen in
arterial blood; PaCO2, partial pressure of carbon dioxide in arterial blood; CRP,
c-reactive protein; PAL, physical activity level; 6-MWD, 6-mins walk distance.
Table 3 Univariate Mixed Effect Model of Annual Change in AIx
Coef. 95% CI p-value
Aortic AIx, (%) 0.83 0.28/1.38 0.003*
Aortic AIx adj. for Baseline, (%) 0.91 0.21/1.60 0.011*
Note: *p-value<0.05.
Abbreviation: AIx, augmentation index.
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to be independently associated with arterial stiffness in COPD
patients in cross-sectional studies.11,28,29 Our data support the
idea of a pathomechanical link between the severity of
emphysema and increased arterial stiffness by showing an
independently positive association between change in DLco
and the course of AIx in COPD patients. Our study does not
Figure 3 The figure shows the estimation of the course of AIx over time according to the influence of change in DLco % pred based on the unadjusted regression model.
The mean (CI) AIx at baseline (0) and follow-up visits (1–4) is estimated for a yearly change in DLco % pred. of −40, −20, 0, and 10.
Abbreviation: DLco, diffusion capacity.
Figure 4 The figure demonstrates the estimated course of AIx over time dependent on hsCRP values based on the unadjusted regression model. The mean (CI) AIx at
baseline (0) and yearly follow-up (1–4) is estimated for hsCRP values of 5, 20, 50 and 70 mg/l.
Abbreviations: AIx, augmentation index; hsCRP, high-sensitivity C-reactive protein.
Dovepress Roeder et al
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provide annual CT-scans to describe the course of emphy-
sema. The main reason was the protection of the study parti-
cipants from unnecessary radiation. Nevertheless, DLco is
a surrogate marker of emphysema in COPD is shown to
represent the severity of tissue destruction in the process of
emphysema development.30,31 Although the exact pathophy-
siological mechanisms are not yet completely understood,
recent findings suggest that increased systemic elastin degra-
dation by matrix metalloproteinases like MMP-9 may lead to
both formation of emphysema and arterial stiffness, depending
on the grade of genetic predisposition.11,32 Maclay et al32
found increased skin elastin degradation in COPD patients
when compared to age and smoking matched healthy controls.
Noteworthy, the upregulated skin elastolysis was associated
with the grade of emphysema and arterial stiffness. In addition,
the inhibition of matrix metalloproteinases in animal models
reduced vascular calcium deposition; a process that reflects the
vascular elastin degradation.33 Smoke exposure plays a key
role in the proteolytic attack against lung tissue, inter alia,
through upregulating MMP in the setting of smoke-induced
inflammation.34 Regarding the increase of arterial stiffness
over time, it seems to be crucial to prevent the progression
of emphysema in COPD patients in clinical practice.
Several cross-sectional studies reported an independent
relationship between the severity of airflow limitation mea-
sured as FEV1 and arterial stiffness in COPD.11,23,35 Sabit
et al8 found an inversed relationship betweenFEV1and arterial
stiffness in 75 clinically stableCOPDpatients. Even thoughwe
Table 4 Univariate Mixed Effect Model of Possible Predictors for
Annual Change in AIx, Adjusted for AIx at Baseline
N=76 Coef. 95% CI p-value
Age, years −0.05 −0.13/0.03 0.215
Male 0.58 −0.78/1.94 0.402
Height, cm 0.04 −0.04/0.11 0.368
Weight, kg 0.02 −0.01/0.05 0.168
BMI, kg/m2 0.06 −0.04/0.15 0.247
Current smoker 0.99 −0.62/2.560 0.227
Pack years of smoking, N 0.00 −0.02/0.03 0.960
Systolic blood pressure, mmHg −0.01 −0.04/0.25 0.690
Diastolic blood pressure, mmHg −0.02 −0.07/0.02 0.264
FEV1, % pred. 0.00 −0.02/0.03 0.849
RV/TLC, % −0.03 −0.07/0.01 0.201
DLco, % pred. 0.02 −0.01/0.04 0.163
PaO2, kPa 0.02 −0.35/0.40 0.907
PaCO2, kPa 0.24 −0.51/1.00 0.530
Number of exacerbations, N −0.04 −0.46/0.38 0.850
Antihypertensivum, N 0.40 −0.89/1.68 0.545
LABA+LAMA+ICS, N 0.23 −0.51/0.98 0.537
Statin, N 1.49 0.08/2.90 0.039*
Arterial hypertension, N 0.52 −0.80/1.84 0.443
CAD, N 2.04 0.09/4.00 0.041*
Diabetes, N 1.43 −0.34/3.20 0.114
hsCRP, mg/l 0.07 0.01/0.12 0.017*
LDL, mmol/l 0.61 0.03/1.18 0.038*
HDL, mmol/l −0.75 −1.66/0.15 0.104
Cholesterol total, mmol/l 0.20 −0.28/0.68 0.408
Triglyceride, mmol/l −0.07 −0.55/0.41 0.769
Survival time, months 0.02 −0.02/0.05 0.269
PAL 0.70 −1.57/2.96 0.548
6MWD, m 0.00 −0.00/0.01 0.537
Note: *p<0.05.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s;
FVC, forced volume capacity; RV, residual volume; TLC, total lung capacity; DLco,
diffusion capacity; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial
pressure of carbon dioxide in arterial blood; LABA, Long-acting beta-agonist;
LAMA, Long-acting muscarinic antagonist; ICS, inhaled corticosteroids; CAD, cor-
onary artery disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
hsCRP, high-sensitivity c-reactive protein; PAL, physical activity level; 6-MWD, 6-min
walk distance.
Table 5 Univariate Mixed Effect Model of Annual Change in
Possible Predictors for Annual Change in AIx, Adjusted for AIx
at Baseline
N=76 Coef. 95% CI p-value
Change in systolic blood pressure, mmHg −0.02 −0.05/0.01 0.293
Change diastolic blood pressure, mmHg −0.02 −0.06/0.02 0.373
Change in FEV1, % pred. −0.04 −0.11/0.03 0.297
Change in RV/TLC, % 0.05 0.00/0.10 0.034*
Change in DLco, % pred. −0.06 −0.12/-0.00 0.036*
Change in PaO2, kPa 0.08 −0.30/0.47 0.664
Change in PaCO2, kPa 0.73 −0.33/1.79 0.179
Change in hsCRP, mg/l −0.02 −0.07/0.03 0.347
Change in LDL, mmol/l −0.68 −1.36/0.01 0.053
Change in HDL, mmol/l −0.46 −2.36/1.44 0.634
Change in Cholesterol total, mmol/l −0.42 −1.09/0.24 0.208
Change in Triglyceride, mmol/l 0.23 −0.42/0.88 0.484
Change in PAL, mmol/l 0.63 −2.18/3.44 0.660
Note: *p<0.05.
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 s;
FVC, forced volume capacity; RV, residual volume; TLC, total lung capacity; DLco,
diffusion capacity; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial
pressure of carbon dioxide in arterial blood; CAD, coronary artery disease; LDL,
low-density lipoprotein; HDL, high-density lipoprotein; hsCRP, high-sensitivity
c-reactive protein; PAL, physical activity level; 6-MWD, 6-mins walk distance.
Table 6 Multivariate Mixed Effect Model of Annual Change in
AIx, Adjusted for AIx at Baseline
Coef. 95% CI p-value
Change in DLco, % pred −0.10 −0.16/-0.04 <0.001*
LDL, mmol/l 1.37 0.48/2.26 0.003*
hsCRP mg/l 0.07 0.01/0.13 0.033*
CAD 3.43 −0.28/7.13 0.070
Notes: *p-value<0.05.
Abbreviations: DLco, diffusion capacity; LDL, low-density lipoprotein; hsCRP,
high-sensitivity c-reactive protein; CAD, coronary artery disease.
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could reproduce this observation at baseline, the course of
arterial stiffness was not predicted by FEV1 or the annual
change in FEV1 in the longitudinal setting. The same observa-
tion was made for PaO2. Cinarka et al36 conducted
a prospective, observational study reporting increased arterial
stiffness in patients with severe COPD and hypoxic states. In
our study, even if low PaO2 was negatively associated with
AIx at baseline, the significance of this observation got lost
looking at the course of AIx over time. Interestingly, these
two conditions could have played a central role in the patho-
mechanical connection between emphysema and arterial stiff-
ness. A possible explanation could be found in the different
study designs. The cross-sectional nature of the studies men-
tioned above could not deliver determinants, indicating the
direction and time-dependent relationships of obstructive
lung function assessments and arterial stiffness. In addition,
cross-sectional associations are at higher risk to be influenced
by unknown confounders.
Arterial stiffness has been suggested as one pathophysio-
logic element linking chronic systemic inflammation and
increased cardiovascular risk.37 Several human and animal-
based studies have shed light on this complex process on
a molecular pathophysiological level. CRP, interleukine-6
(IL-6) and endothelin-1 production can alter NO synthesis,
which, in turn, could lead to endothelial dysfunction. In addi-
tion, increased IL-6 and TNF-α could increase the expression
of adhesion molecules on activated endothelial cells and facil-
itate the formation of atheromatous plaques.38,39 In this study,
hsCRP was independently associated with the evolution of
arterial stiffness over time supporting the hypothesis that sys-
temic inflammation could be an important determinant in the
development of increased arterial stiffness and further cardio-
vascular risk in COPD patients. Although dyslipidaemia is
a well-known, independent risk factor for cardiovascular dis-
ease, the relationship between serum lipids and arterial stiff-
ness is still under debate.Wang et al40 conducted a population-
based, cross-sectional study with 2375 participants investigat-
ing the relationship between serum lipids and PWV. They
found LDL to be independently positive and HDL indepen-
dently inversely associated with arterial stiffness. Our data
confirmed these findings in a longitudinal setting, even though
the association between HDL and AIx course did not quite
reach statistical significance. The intake of statins showed
a high correlation to elevated LDL values and was therefore
not analysed in our final statistical model. Nevertheless, these
findings underline the crucial need to check for dyslipidaemia
to initiate aggressive lipid-lowering therapy in COPD patients.
Several previous studies determined arterial stiffness not only
as an independent predictor of cardiovascular events but also
of all-cause mortality.6 In this study, shorter survival time was
not associated with a steeper rise of AIx over time.
Nevertheless, the negative association between survival time
and AIx at baseline with barely missed statistical significance
(p=0.081) could suggest that the period of longitudinal obser-
vation might be too short to show an association between
survival time and course of AIx. Some classical risk factors
like BP, smoking status, and PA showed no association to the
course of arterial stiffness, even though these conditions had
been described as significantly influencing arterial stiffness.
However, the postulated link between these factors and arterial
stiffness inCOPDisdrivenbycross-sectional data.Mills et al41
assessed arterial stiffness in 102 COPD patients and 103
healthy controls matched for age and smoking status. The
cross-sectional analysis revealed increased arterial stiffness
in COPD patients which was positively associated with dia-
stolic and systolic BP. We could confirm this association
through analysing arterial stiffness and BP cross-sectional at
baseline. Nevertheless, no statistically significant association
was detectable between BP, its changes, and the course of AIx
in the longitudinal analysis, thus leading to the conclusion that
elevated BP might only play a minor role in the development
of arterial stiffness in COPD. In contrast to former cross-
sectional studies,7 increased PA or exercise capacity had no
impact on the increase of AIx over time.
Limitations
There are some limitations to our study. A recent review about
aging and arterial stiffness pointed out, that changes of arterial
stiffness measured by AIx are more prominent in younger
patients, whereas the changes in aortic PWVare more marked
in patients older than 50 years.25 As a result, the increasing
arterial stiffness over time might still be underestimated in our
cohort. Furthermore, since several patients with very severe
COPD were unable to follow our invitations due to worsening
health status, the influence of airflow limitation on the course
of arterial stiffness could be underestimated; despite the AIx at
baseline being no different. In addition, the protocol did not
provide the formation and investigation of a control group.
Therefore, we could not directly compare the natural increase
in AIx with the course of AIx in COPD patients. Nonetheless,
little information is available on patterns and determinants of
longitudinal change in arterial stiffness in COPD.
Conclusion
To our knowledge, this is the first longitudinal study illustrat-
ing the course of arterial stiffness in COPDmeasured by AIx
Dovepress Roeder et al
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over time. Our data clearly demonstrated an annual increase
of arterial stiffness in patients with COPD, which was inde-
pendently associated with the course of CO diffusion capa-
city, serum lipids, and inflammation. Further studies are
needed to elucidate the complex interactions between these
factors in order to understand their clinical implication.
Abbreviations
AE, acute exacerbation; Aix, Augmentation index; BMI, body
mass index; CI, confidence interval; Coef., coefficient; COPD,
chronic obstructive pulmonary disease; hsCRP, high-
sensitivity c-reactive protein; DLco, diffusing capacity of the
lung for carbonmonoxide; GOLD, global initiative for chronic
obstructive lung disease; FEV1, forced expiratory volume in 1
s; FVC, forced vital capacity; HDL, high-density lipoprotein;
HR, hazard ratio; IQR, interquartile range; LDL, low-density
lipoprotein; MMP, matrix metalloproteinases; mMRC, modi-
fied British Medical Research Council; PA, physical activity;
PAL, physical activity level; PWV, pulse-wave velocity; RV/
TLC, residual volume to total lung capacity; SD, standard
deviation; TG, triglyceride; TOPDOCS, The Obstructive
Pulmonary Disease Outcomes Cohort Study; 6MWD, 6-mins
walk distance.
Data Sharing Statement
The datasets used and/or analysed during the current study
are available from the corresponding author on reasonable
request.
Acknowledgment
This study was supported by Lunge Zurich.
Author Contributions
All authors made substantial contributions to conception
and design, acquisition of data, or analysis and interpreta-
tion of data; took part in drafting the article or revising it
critically for important intellectual content; gave final
approval of the version to be published; and agree to be
accountable for all aspects of the work.
Disclosure
Prof. Dr. Malcolm Kohler reports grants and personal fees
from Bayer, personal fees from Novartis, personal fees from
Boehringer, personal fees fromGSK, personal fees fromAstra
Zeneca, grants from Roche, personal fees from CSL Behring,
and personal fees from Mundipharma, during the conduct of
the study. The authors report no other conflicts of interest in this
work.
References
1. Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and
prevention. COPD. 2010;7:375–382. doi:10.3109/15412555.2010.
510160
2. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary
disease: a modifiable risk factor for cardiovascular disease? Heart.
2012;98:1055–1062.
3. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular
comorbidity in patients with chronic obstructive pulmonary disease:
a systematic review and meta-analysis. Lancet Respir Med.
2015;3:631–639. doi:10.1016/S2213-2600(15)00241-6
4. Lee HM, Lee J, Lee K, et al. Relation between COPD severity and
global cardiovascular risk in US adults. Chest. 2012;142:1118–1125.
doi:10.1378/chest.11-2421
5. Vivodtzev I, Tamisier R, Baguet JP, et al. Arterial stiffness in COPD.
Chest. 2014;145:861–875. doi:10.1378/chest.13-1809
6. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardio-
vascular events and all-cause mortality with arterial stiffness:
a systematic review and meta-analysis. J Am Coll Cardiol.
2010;55:1318–1327. doi:10.1016/j.jacc.2009.10.061
7. Sievi NA, Franzen D, Kohler M, et al. Physical inactivity and arterial
stiffness in COPD. Int J Chron Obstruct Pulmon Dis.
2015;10:1891–1897. doi:10.2147/COPD.S90943
8. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteo-
porosis in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med. 2007;175:1259–1265. doi:10.1164/rccm.200701-067OC
9. Gale NS, Albarrati AM,MunneryMM, et al. Aortic pulse wave velocity
as a measure of cardiovascular risk in chronic obstructive pulmonary
disease: two-year follow-up data from the ARCADE study. Medicina
(Kaunas). 2019;55:89. doi:10.3390/medicina55040089
10. Sarkar MJER. Chronic obstructive pulmonary disease and arterial
stiffness. EMJ Respir. 2016;4:114–121.
11. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is
independently associated with emphysema severity in patients with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
2007;176:1208–1214. doi:10.1164/rccm.200707-1080OC
12. Vanfleteren LE, Spruit MA, Groenen MT, et al. Arterial stiffness in
patients with COPD: the role of systemic inflammation and the
effects of pulmonary rehabilitation. Eur Respir J.
2014;43:1306–1315. doi:10.1183/09031936.00169313
13. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary dis-
ease - GOLD executive summary. Am J Respir Crit Care Med.
2007;176:532–555. doi:10.1164/rccm.200703-456SO
14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of
spirometry. Eur Respir J. 2005;26:319–338. doi:10.1183/09031
936.05.00034805
15. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the
single-breath determination of carbon monoxide uptake in the lung.
Eur Respir J. 2005;26:720–735. doi:10.1183/09031936.05.00034905
16. Van Remoortel H, Raste Y, Louvaris Z, et al. Validity of six activity
monitors in chronic obstructive pulmonary disease: a comparison
with indirect calorimetry. PLoS One. 2012;7:e39198. doi:10.1371/
journal.pone.0039198
17. Watz H, Waschki B, Meyer T, et al. Physical activity in patients with
COPD. Eur Respir J. 2009;33:262. doi:10.1183/09031936.00024608
18. Holland AE, Spruit MA, Troosters T, et al. An official European
Respiratory Society/American Thoracic Society technical standard:
field walking tests in chronic respiratory disease. Eur Respir J.
2014;44:1428–1446. doi:10.1183/09031936.00150314
Roeder et al Dovepress
submit your manuscript | www.dovepress.com
DovePress





















































































































Powered by TCPDF (www.tcpdf.org)
19. WHO. International Classification of Diseases (ICD). 2013. Available
from: http://www.who.int/classifications/icd/en/. Accessed September
21, 2013.
20. Pauca Alfredo L, O’Rourke Michael F, Kon Neal D. Prospective
evaluation of a method for estimating ascending aortic pressure
from the radial artery pressure waveform. Hypertension.
2001;38:932–937. doi:10.1161/hy1001.096106
21. Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart
rate on augmentation index and central arterial pressure in humans.
J Physiol. 2000;525(Pt 1):263–270. doi:10.1111/j.1469-7793.2000.
t01-1-00263.x
22. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate depen-
dency of pulse pressure amplification and arterial stiffness. Am
J Hypertens. 2002;15:24–30. doi:10.1016/S0895-7061(01)02252-X
23. Albu A, Fodor D, Bondor C, et al. Carotid arterial stiffness in patients
with chronic obstructive pulmonary disease. Acta Physiol Hung.
2011;98:117–127. doi:10.1556/APhysiol.98.2011.2.3
24. Janner JH, Godtfredsen NS, Ladelund S, et al. The association
between aortic augmentation index and cardiovascular risk factors
in a large unselected population. J Hum Hypertens.
2012;26:476–484. doi:10.1038/jhh.2011.59
25. Lee H-Y, Oh B-H. Aging and arterial stiffness. Circ J.
2010;74:2257–2262. doi:10.1253/circj.CJ-10-0910
26. Wu C-F, Liu P-Y, Wu T-J, et al. Therapeutic modification of arterial
stiffness: an update and comprehensive review. World J Cardiol.
2015;7:742–753. doi:10.4330/wjc.v7.i11.742
27. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology,
and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol.
2005;25:932–943. doi:10.1161/01.ATV.0000160548.78317.29
28. Barr RG, Ahmed FS, Carr JJ, et al. Subclinical atherosclerosis, air-
flow obstruction and emphysema: the MESA lung study. Eur Respir
J. 2012;39:846–854. doi:10.1183/09031936.00165410
29. Duckers JM, Shale DJ, Stockley RA, et al. Cardiovascular and
musculoskeletal co-morbidities in patients with alpha 1 antitrypsin
deficiency. Respir Res. 2010;11:173. doi:10.1186/1465-9921-11-173
30. Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates
with measurements of airflow limitation and the diffusing capacity.
Eur Respir J. 1991;4:141–146.
31. Scharf SM, Iqbal M, Keller C, et al. Hemodynamic characterization
of patients with severe emphysema. Am J Respir Crit Care Med.
2002;166:314–322. doi:10.1164/rccm.2107027
32. Maclay JD, McAllister DA, Rabinovich R, et al. Systemic elastin
degradation in chronic obstructive pulmonary disease. Thorax.
2012;67:606–612. doi:10.1136/thoraxjnl-2011-200949
33. Qin X, Corriere MA, Matrisian LM, et al. Matrix metalloproteinase
inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol.
2006;26:1510–1516. doi:10.1161/01.ATV.0000225807.76419.a7
34. Churg A, Zhou S, Wright JL. Matrix metalloproteinases in COPD.
Eur Res J . 2012;39:197–209. doi:10.1183/09031936.00121611
35. Zureik M, Benetos A, Neukirch C, et al. Reduced pulmonary function
is associated with central arterial stiffness in men. Am J Respir Crit
Care Med. 2001;164:2181–2185. doi:10.1164/ajrccm.164.12.2107
137
36. Cinarka H, Kayhan S, Gumus A, et al. Arterial stiffness measured via
carotid femoral pulse wave velocity is associatedwith disease severity in
COPD. Respir Care. 2014;59:274–280. doi:10.4187/respcare.02621
37. Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of flutica-
sone propionate/salmeterol on arterial stiffness in patients with
COPD. Respir Med. 2011;105:1322–1330. doi:10.1016/j.rmed.
2011.05.016
38. Cortez-Cooper M, Meaders E, Stallings J, et al. Soluble TNF and
IL-6 receptors: indicators of vascular health in women without car-
diovascular disease. Vasc Med. 2013;18:282–289. doi:10.1177/
1358863X13508336
39. Hung MJ, Cherng WJ, Hung MY, et al. Interleukin-6 inhibits
endothelial nitric oxide synthase activation and increases endothelial
nitric oxide synthase binding to stabilized caveolin-1 in human vas-
cular endothelial cells. J Hypertens. 2010;28:940–951. doi:10.1097/
HJH.0b013e32833992ef
40. Wang F, Ye P, Luo L, et al. Association of serum lipids with arterial
stiffness in a population-based study in Beijing. Eur J Clin Invest.
2011;41:929–936. doi:10.1111/eci.2011.41.issue-9
41. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in
patients with chronic obstructive pulmonary disease: a mechanism for
increased cardiovascular risk. Thorax. 2008;63:306. doi:10.1136/
thx.2007.083493
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
Publish your work in this journal
The International Journal of COPD is an international, peer-reviewed
journal of therapeutics and pharmacology focusing on concise rapid
reporting of clinical studies and reviews in COPD. Special focus is
given to the pathophysiological processes underlying the disease, inter-
vention programs, patient focused education, and self management
protocols. This journal is indexed on PubMed Central, MedLine
and CAS. The manuscript management system is completely online
and includes a very quick and fair peer-review system, which is
all easy to use. Visit http://www.dovepress.com/testimonials.php to
read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal
Dovepress Roeder et al























































































































Powered by TCPDF (www.tcpdf.org)
